Actorise 25 Injection (Alteplase)
Price range: $91.88 through $207.46Required
| Pack Size | Price | Unit Price | Quantity | |
|---|---|---|---|---|
| 2 Injection | $91.88 | $45.94 / injection | ||
| 4 Injection | $151.54 | $37.89 / injection | ||
| 6 Injection | $207.46 | $34.58 / injection |
About Actorise 25 Injection (Alteplase)
Medicine information
- Active ingredient
- Darbepoetin alfa
- Indication
- Treatment of anaemia associated with chronic kidney disease and chemotherapy-associated anaemia in appropriate patients with non-myeloid malignancies. Actorise 25 Injection is not an alteplase product; current product listings identify Actorise 25 as darbepoetin alfa 25 mcg/0.42 mL.
- Manufacturer
- Cipla Ltd
- Packaging
- 1 prefilled syringe containing 0.42 mL
- Strength
- 25 mcg
- Dosage form
- Solution for injection in prefilled syringe
- Route
- Subcutaneous or intravenous
Medicine overview
Actorise 25 Injection contains darbepoetin alfa 25 mcg in a 0.42 mL prefilled syringe. It is an erythropoiesis-stimulating agent (ESA), a medicine that encourages the bone marrow to make red blood cells. Darbepoetin alfa is used to manage certain types of anaemia associated with chronic kidney disease and chemotherapy. The medicine is administered by injection and requires medical supervision, appropriate haemoglobin monitoring, and careful management of cardiovascular and blood-clot risks.
What it is used for
Darbepoetin alfa is used to treat anaemia associated with chronic kidney disease. It is also used for anaemia caused by myelosuppressive chemotherapy in selected patients with non-myeloid cancers. Treatment is intended to stimulate red blood cell production and, in appropriate settings, reduce the need for red blood cell transfusions. Its use in cancer-related anaemia is subject to important restrictions because ESAs can increase serious cardiovascular, thromboembolic, and cancer-related risks.
How it works
Darbepoetin alfa acts like erythropoietin, a natural hormone produced mainly by the kidneys. Erythropoietin signals the bone marrow to produce red blood cells. Chronic kidney disease can reduce natural erythropoietin production, while chemotherapy can suppress red blood cell formation. Darbepoetin alfa binds to erythropoietin receptors on blood-forming cells and stimulates red blood cell production, gradually increasing haemoglobin when the patient responds to treatment.
How it is taken
Actorise 25 Injection is administered by injection. Darbepoetin alfa can be given subcutaneously, meaning under the skin, or intravenously, meaning into a vein, depending on the indication and clinical circumstances. The dose and treatment interval must be determined from the patient's condition, haemoglobin response and other clinical factors. Patients or caregivers should administer darbepoetin alfa themselves only when specifically instructed and trained by a healthcare professional.
Important warnings
Do not use darbepoetin alfa in patients with uncontrolled hypertension or in patients who have developed pure red cell aplasia following treatment with darbepoetin alfa or another erythropoietin protein. ESAs can increase the risks of death, myocardial infarction, stroke, venous thromboembolism and vascular-access thrombosis. In patients with cancer, ESAs may increase the risk of tumour progression or recurrence in some settings. Blood pressure should be controlled before and during treatment. Severe allergic reactions and serious skin reactions can occur. New or worsening seizures require medical assessment. If haemoglobin does not respond as expected, causes such as iron deficiency, bleeding, infection or pure red cell aplasia should be investigated.
Side effects and monitoring
Common or clinically important effects reported with darbepoetin alfa in chronic kidney disease include hypertension, shortness of breath, peripheral oedema, cough, low blood pressure associated with procedures, rash and vascular-access complications. Injection-site pain can also occur. Serious risks include blood clots, heart attack, stroke, seizures, severe hypertension, severe allergic reactions and pure red cell aplasia. Haemoglobin and blood pressure require regular monitoring; iron status should also be evaluated because adequate iron is needed for red blood cell production. Seek urgent medical attention for chest pain, sudden breathing difficulty, one-sided weakness, severe headache, seizures, symptoms of a blood clot, or a serious allergic reaction.
Pregnancy
Available human pregnancy data are insufficient to determine whether darbepoetin alfa causes major birth defects or miscarriage. Treatment during pregnancy requires consideration of the expected maternal benefit and possible fetal risks.
Breastfeeding
It is not known whether darbepoetin alfa is present in human milk, affects a breastfed child, or affects milk production. The benefits of breastfeeding should be considered together with the mother's clinical need for treatment and any potential risk to the infant.
Storage
Store refrigerated at 2°C to 8°C. Do not freeze or shake. Protect from light and keep the prefilled syringe in its original carton until use. A syringe that has been frozen or improperly handled should not be used.
Frequently asked questions
Is Actorise 25 Injection alteplase?
No. Current product records identify Actorise 25 Injection as darbepoetin alfa 25 mcg/0.42 mL, not alteplase. Alteplase is a different medicine used to dissolve certain blood clots.
How quickly will Actorise raise my haemoglobin?
Darbepoetin alfa stimulates new red blood cell production rather than providing an immediate increase. Haemoglobin response is monitored with blood tests, and treatment decisions are based on the patient's response.
Why do I need blood tests while receiving Actorise?
Blood tests help monitor haemoglobin response and identify factors such as iron deficiency that can limit treatment effectiveness. Monitoring also helps reduce risks associated with an excessive haemoglobin response.
Can Actorise cause high blood pressure?
Yes. Hypertension is a recognised adverse effect of darbepoetin alfa, and uncontrolled hypertension is a contraindication. Blood pressure should be controlled before treatment and monitored during therapy.
Why might Actorise not improve my anaemia?
A poor response can have several causes, including iron deficiency, infection, inflammation, bleeding or, rarely, pure red cell aplasia. A healthcare professional should investigate an inadequate response rather than simply increasing treatment without assessment.
Can Actorise increase the risk of blood clots?
Yes. Erythropoiesis-stimulating agents such as darbepoetin alfa can increase thromboembolic and cardiovascular risks, including stroke, heart attack and vascular-access thrombosis.
Can I inject Actorise myself at home?
Only if your healthcare professional has specifically instructed and trained you to do so. Darbepoetin alfa may be given under the skin or into a vein depending on the clinical situation.
Does Actorise need refrigeration?
Yes. Darbepoetin alfa prefilled syringes should be stored at 2°C to 8°C, protected from light, and must not be frozen or shaken.
Can Cheap Generic Med ship Actorise internationally?
NOT VERIFIED
Sources
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
| Packaging | Qty |
|---|---|
| Delivery Time | 6 To 15 days |
Related products
Combutol 200 Mg (Ethambutol)
Combutol 800 Mg (Ethambutol)
Gingko Plus (Natural)
Mesacol 800 Mg (Mesalamine)
Mucinac 600 Mg (N-acetylcysteine)
Mycobutol 800 Mg (Ethambutol)
Mycofit 250 Mg (Mycophenolate Mofetil)
Reviews
There are no reviews yet.